NCT06986057View on ClinicalTrials.gov

Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions

Cervical CancerNeoadjuvant Therapy

Interventions

DRUG

Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy

Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy

All Listed Sponsors

lead

Shandong Tumor Hospital

OTHER